- Home
- LCID vs ITCI Comparison
LCID vs ITCI Comparison
Compare LCID & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCID
- ITCI
- Stock Information
- Founded
- LCID 2007
- ITCI 2002
- Country
- LCID United States
- ITCI United States
- Employees
- LCID N/A
- ITCI N/A
- Industry
- LCID Auto Manufacturing
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- LCID Consumer Discretionary
- ITCI Health Care
- Exchange
- LCID Nasdaq
- ITCI Nasdaq
- Market Cap
- LCID 9.0B
- ITCI 8.7B
- IPO Year
- LCID N/A
- ITCI N/A
- Fundamental
- Price
- LCID $2.96
- ITCI $126.89
- Analyst Decision
- LCID Hold
- ITCI Buy
- Analyst Count
- LCID 9
- ITCI 13
- Target Price
- LCID $3.18
- ITCI $100.31
- AVG Volume (30 Days)
- LCID 100.3M
- ITCI 2.9M
- Earning Date
- LCID 02-25-2025
- ITCI 02-20-2025
- Dividend Yield
- LCID N/A
- ITCI N/A
- EPS Growth
- LCID N/A
- ITCI N/A
- EPS
- LCID N/A
- ITCI N/A
- Revenue
- LCID $730,510,000.00
- ITCI $613,728,000.00
- Revenue This Year
- LCID $33.01
- ITCI $48.41
- Revenue Next Year
- LCID $84.40
- ITCI $38.26
- P/E Ratio
- LCID N/A
- ITCI N/A
- Revenue Growth
- LCID 4.98
- ITCI 46.08
- 52 Week Low
- LCID $1.93
- ITCI $62.78
- 52 Week High
- LCID $4.43
- ITCI $128.00
- Technical
- Relative Strength Index (RSI)
- LCID 53.11
- ITCI 87.18
- Support Level
- LCID $2.85
- ITCI $80.83
- Resistance Level
- LCID $3.64
- ITCI $128.00
- Average True Range (ATR)
- LCID 0.28
- ITCI 2.57
- MACD
- LCID -0.04
- ITCI 4.45
- Stochastic Oscillator
- LCID 13.92
- ITCI 97.65
About LCID Lucid Group Inc.
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.